Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc.
Your view on SNOA
Overview
What the company does, where it operates, and who runs it.
About Sonoma Pharmaceuticals, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Amy M. Trombly
- Headquarters
- 645 Molly Lane, Woodstock, GA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Amy M. Trombly
- Headquarters
- 645 Molly Lane, Woodstock, GA, US
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally.
The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds.
In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sonoma Pharmaceuticals, Inc., and the rating behind it. SNOA last traded at $1.30; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sonoma Pharmaceuticals, Inc.. Starting points for Sonoma Pharmaceuticals, Inc.: EPS -$0.59, beta 1.31 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sonoma Pharmaceuticals, Inc.. Sonoma Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sonoma Pharmaceuticals, Inc.. Trailing twelve-month EPS for Sonoma Pharmaceuticals, Inc. stands at -$0.59. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sonoma Pharmaceuticals, Inc.. Sonoma Pharmaceuticals, Inc. has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sonoma Pharmaceuticals, Inc. valued side by side against its closest peers. Sonoma Pharmaceuticals, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sonoma Pharmaceuticals, Inc., and how their positions are changing. At a $2.2M market value, institutional positions materially move Sonoma Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sonoma Pharmaceuticals, Inc. executives and directors. Shares of Sonoma Pharmaceuticals, Inc. have traded between $1.75 and $6.92 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sonoma Pharmaceuticals, Inc.. Sonoma Pharmaceuticals, Inc. is a $2.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sonoma Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sonoma Pharmaceuticals, Inc.. Coverage tracks Sonoma Pharmaceuticals, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.